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Aims AUGMENT-HF was an international, multi-centre, prospective, randomized, controlled trial to evaluate the benefits
and safety of a novel method of left ventricular (LV) modification with alginate-hydrogel.
Methods Alginate-hydrogel is an inert permanent implant that is directly injected into LV heart muscle and serves as a prosthetic
scaffold to modify the shape and size of the dilated LV. Patients with advanced chronic heart failure (HF) were rando-
mized (1 : 1) to alginate-hydrogel (n ¼ 40) in combination with standard medical therapy or standard medical therapy
alone (Control, n ¼ 38). The primary endpoint of AUGMENT-HF was the change in peak VO2 from baseline to
6 months. Secondary endpoints included changes in 6-min walk test (6MWT) distance and New York Heart Associ-
ation (NYHA) functional class, as well as assessments of procedural safety.
Results Enrolled patients were 63+10 years old, 74% in NYHA functional class III, had a LV ejection fraction of 26+5% and a
mean peak VO2 of 12.2+1.8 mL/kg/min. Thirty-five patients were successfully treated with alginate-hydrogel injec-
tions through a limited left thoracotomy approach without device-related complications; the 30-day surgical mortality
was 8.6% (3 deaths). Alginate-hydrogel treatment was associated with improved peak VO2 at 6 months—treatment
effect vs. Control: +1.24 mL/kg/min (95% confidence interval 0.26–2.23, P ¼ 0.014). Also 6MWT distance and
NYHA functional class improved in alginate-hydrogel-treated patients vs. Control (both P, 0.001).
Conclusion Alginate-hydrogel in addition to standard medical therapy for patients with advanced chronic HF was more effective
than standard medical therapy alone for improving exercise capacity and symptoms. The results of AUGMENT-HF
provide proof of concept for a pivotal trial.
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Introduction
Heart failure (HF) is a major health problem worldwide with 5-year
mortality rates that exceed 50%.1 As HF progresses, the heart
undergoes progressive left ventricular (LV) remodelling. According
to the principle of Laplace’s law, as the LV dilates and LV wall thins,
and wall stress increases, resulting in continued myocardial damage.
Unless an intervention can break this deleterious spiral of events, HF
will continue to progress with worsening LV dilation. Left ventricu-
lar remodelling is maladaptive and its progression contributes to
worsening of clinical symptoms, marked exercise intolerance, and
congestion, all of which culminate in hospitalizations due to HF de-
compensation and premature death of the afflicted patient.
Despite recent advances in therapy, morbidity and mortality re-
sulting from HF remain unacceptably high.2 The use of tissue engin-
eering principles to improve myocardial functionality has shown
encouraging preclinical results.3 – 5 The concept of LV modification
or restoration with the intra-myocardial injection of an alginate-
based polymer results in increased wall thickness and a change of
LV geometry.6 In a canine model of HF, LV injection/implantation
with an alginate-based formulation led to improvement in indexes
of LV systolic function without negatively impacting LV relaxation
or filling.7 In a prior clinical study evaluating the safety and feasibility
of alginate-hydrogel administered at the time of cardiac bypass sur-
gery, there were observations of an increase in LV wall thickness, re-
duction of end-diastolic volume, and end-systolic volume as well as
decreases in myocardial wall stress at end-diastole and end-systole
over 3–6 months.8
The AUGMENT-HF clinical trial was designed to evaluate the
benefits and safety of treatment with alginate-hydrogel in patients
with advanced chronic HF.
Methods
Study design and protocol
AUGMENT-HF was an international, multi-centre, prospective, rando-
mized, controlled clinical trial of alginate-hydrogel in patients with ad-
vanced chronic HF. Eligible patients were randomly allocated to
receive either alginate-hydrogel in addition to standard medical therapy
or standard medical therapy alone (Control). Randomization was strati-
fied for two variables: aetiology of cardiomyopathy (ischaemic vs. non-
ischaemic) and baseline peak VO2 (greater than or ≤12.5 mL/kg/min).
The study included patients aged 18–79 years, who had a peak VO2
of 9.0–14.5 mL/kg/min, a left ventricular ejection fraction (LVEF)
≤35%, a left ventricular end-diastolic dimension indexed to body sur-
face area of 30–40 mm/m2, and were required to be on stable,
evidence-based therapy for HF. Primary exclusion criteria were an LV
wall thickness ,0.8 cm (mid-ventricular level), a serum creatinine
.2.5 mg/dL, clinically significant liver enzyme abnormalities, Q-wave
myocardial infarction (MI) within the last 30 days, or a history of stroke
within 60 days.
Core laboratories, blinded to treatment assignment, conducted the
evaluation of key measures of cardiopulmonary exercise (CPX) testing
(peak VO2), cardiac imaging (echocardiography), Holter monitors, and
laboratory evaluations. Blinded endpoint assessment was used to com-
pensate partially for the fact that the trial could not be truly double
blind. Sham thoracotomy and intra-myocardial injection (with no pro-
spect of improvement) in the control patients were not considered eth-
ically acceptable. We used, as the basis for the primary endpoint peak
VO2, which is objective in as much as it measures an objective physio-
logical variable, recognizing it remains subject to bias in the form of dif-
ferential effort during exercise testing, in that the patient knows whether
or not he/she had undergone surgery. We measured peak achieved re-
spiratory exchange rate (RER) as a measure of exercise effort, to assess
if the randomized groups would demonstrate any differential effort in
follow-up exercise tests. An independent clinical events committee
(CEC) adjudicated all events suggestive of study endpoints, including
major adverse cardiac events (MACE), whilst blinded to treatment
group allocation. Major adverse cardiac events were defined as cardiac
death, cardiac arrest, MI, sustained ventricular arrhythmias, pulmonary
oedema, acute HF, unstable angina, and major bleeding. A Data Safety
Management Board provided an independent ongoing assessment of
safety.
The study was conducted at 14 centres in Australia, Germany, Italy,
the Netherlands, and Romania. The protocol was approved by the regu-
latory authorities in each country and the local Ethics Committees. The
study was conducted in accordance with the principles of the Declar-
ation of Helsinki, the International Conference on Harmonization
Good Clinical Practice guidelines, and local and national regulations.
Written informed consent was provided by all patients.
The trial protocol defined an initial study report on efficacy (exercise
tolerance) to be generated after every patient had been followed for a
minimum of 6 months and a final ‘extended follow-up phase’ study re-
port focusing on long-term safety after 24 months follow-up. First enrol-
ment occurred in May 2012, and enrolment was completed in April
2014. This paper provides the report on the primary results analyses
for 6 months of follow-up.
Investigations
After signing informed consent, each patient underwent a baseline
screening assessment including CPX testing and assessment of 6-min
walk test (6MWT) distance. In addition, at specific visits echocardiog-
raphy assessments were performed, quality-of-life questionnaires
were completed, and safety blood samples were taken. To investigate
for potential ventricular ectopy, 24-h-Holter monitoring was performed
at screening as well as 3 and 6 months. Holter recordings were digitally
stored and assessed by central blinded review (BioClinica Cardiovascu-
lar Safety Services).
Patients were required to perform two CPX tests within 30 days of
randomization and performed at least 20 h apart that differed by no
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.15% in the observed value for peak VO2 (as per Core laboratory re-
port). Cardiopulmonary exercise could be repeated a third time,
if needed. Patients meeting the entry criteria (based on the mean of
the last two assessments) were randomized to alginate-hydrogel
or Control.
Training on standardized procedures for conduct of CPX testing and
validation testing were required for each clinic prior to study initiation.
Revalidation was required every 6 months. Cardiopulmonary exercise
data were uploaded to the blinded core lab for analysis and the core la-
boratory provided rapid feedback on test quality for each test. Analyses
of CPX measures were determined from averaged 10 s gas exchange
data from the start to the end of exercise. Patients returned to the clinic
at 3 and 6 months post-discharge for follow-up evaluations. Patients
were required to complete one CPX test at 3 months, and two CPX
tests at the 6 months (with the average value for these two tests being
employed in analyses).
Therapy
Patients randomized to the investigational device group had alginate-
hydrogel (calcium-alginate-hydrogel) administered during a surgical
procedure as previously described.8 The approximate locations of
alginate-hydrogel injections and technical details are presented in Figure 1.
Statistical methods
The primary efficacy endpoint in this study was the change in peak VO2
from baseline to 6 months. The primary safety objective was to estimate
the 30-day mortality associated with the implantation of alginate-
hydrogel. Six-minute walk test distance, quality of life as measured by
Kansas City Cardiomyopathy Questionnaire (KCCQ), patient global as-
sessment (PGA), New York Heart Association (NYHA) functional class,
CPX measures of peak watts and total exercise time, and measures of
echocardiographic imaging were all pre-specified secondary endpoints.
Statistical significance was attached to P-values of ,0.05 (SAS version
9.3; SAS institute).
Data analysis were performed according to intention to treat. The
primary and secondary efficacy analyses were performed on the modi-
fied intention-to-treat (mITT) analysis population, which included all
randomized patients (Control group) and for the alginate-hydrogel
group, all patients randomized to the alginate-hydrogel group for
whom the surgery to implant the alginate-hydrogel device was started.
The safety analysis dataset comprised all randomized patients. No im-
putation was performed for missing data.
To test the group differences for the primary outcome, a repeated-
measures mixed model was used with an unstructured covariance ma-
trix to model the within-patient variability. The same model was used to
test the group differences for echocardiographic imaging results and
KCCQ data. It was pre-specified that non-normally distributed data
were to be analysed using non-parametric testing, which was the case
for 6MWT distance. The treatment effect for NYHA functional class
at 6 months was compared by means of logistic regression with ordinal
polytomous response adjusted for baseline.
Cumulative survival curves for the time-to-event analyses were con-
structed according to the Kaplan–Meier method and differences were
examined by the log-rank statistic. The Cox proportional hazards re-
gression (SAS proc phreg procedure) was used to estimate the hazard
ratios with treatment as the only covariate. Event rates were expressed
as the percentage of events per 100 patient-years of follow-up, taking
into account the censoring of follow-up data. The repeated-measures
analysis for categorical variables was done using the SAS proc logistic
procedure including terms for treatment and baseline value.
The primary safety endpoint for the study was 30-day all-cause mor-
tality in patients randomized to alginate-hydrogel for whom the alginate-
hydrogel device was implanted. The starting point for the 30-day count
was the start of surgery. The 30-day all-cause mortality associated with
the implantation of the alginate-hydrogel device was to be qualitatively
compared with the observed rate of 5%, estimated based upon three re-
cently completed clinical trials that investigated similar patient popula-
tions and evaluated surgical ventricular reconstruction or the CorCap
device.9,10 Assuming the 30-day mortality rate is consistent with the es-
timated 5% rate and a sample size of N ¼ 38, the estimate was that the
Figure 1 Algisyl-LVR implantation. Standardization of the
placement of the implants at the mid-ventricular level identified
as the halfway point between the left ventricular base (defined
as the atrioventricular groove) and apex (A). The implants are
equally spaced in the mid-myocardium starting at the antero-septal
groove and ending at the postero-septal groove (B). Note:
alginate-hydrogel (LoneStar Heart, Inc., Laguna Hills, CA, USA) is
a proprietary calcium-alginate-hydrogel that consists of two com-
ponents: an Na+-alginate component supplied as a sterile aqueous
solution with 4.6% mannitol and a Ca2+-alginate component con-
sisting of water insoluble particles suspended in a sterile 4.6% man-
nitol solution. These two components are mixed immediately
before use, and then combined in one syringe for delivery as intra-
myocardial injections. Alginate-hydrogel is administered during a
surgical procedure. A left thoracotomy is performed to expose
the heart and the pericardium. The left ventricular free wall was
identified and the injection sites marked with a surgical marker.
In total, 10–19 intra-myocardial injections were made on the beat-
ing heart, circumferentially, at the left ventricular mid-ventricular
level halfway between the left ventricular apex and base starting
at the antero-septal groove and ending at the postero-septal
groove. Left ventricular wall thickness must not have been
,8 mm at the locations where the alginate-hydrogel was to be in-
jected. The total number of injections administered for an individ-
ual patient depended on the size of the heart (amount of space
available on the LV-free wall). All injections were made along or
within 1 cm of a single mid-ventricular line, being careful to avoid
any visible coronary vasculature. Standardization of the placement
of the implants was performed via the identification of standard
anatomical features (atrioventricular groove and apex). Injections
of 0.3 mL of alginate-hydrogel were separated by 0.5–1 cm and
made at the mid-wall depth of the myocardium.
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observed mortality in this study would be between 0.1 and 17.4%
with 95% confidence (calculations performed using PASS 2008 and
the Exact (Clopper Pearson) confidence interval formula). Based on
the binomial distribution, a sample size of 38 patients, and a probability
of post-surgical mortality equal to 5%, the probability of observing four
or fewer deaths was 96.0%. The probability of observing five or more
deaths was 4.0%.
Results
In total, 113 patients were screened for the study, and 35 patients
were found to be ineligible or declined participation at screening.
A total of 78 patients were randomized (1 : 1) to alginate-hydrogel
(n ¼ 40) and Control (n ¼ 38). The procedure to implant the
alginate-hydrogel device was not performed in five patients rando-
mized to this treatment group. Two of these patients were found to
have a LV thrombus (echocardiography) on the day prior to the
planned surgical procedure and deemed therefore ineligible. Three
patients withdrew consent after randomization to the alginate-
hydrogel group and prior to the surgical procedure. All other pa-
tients randomized to the alginate-hydrogel (n ¼ 35) underwent a
successful surgical procedure to implant the device; there were
no failures to implant the device.
Demographics and baseline characteristics for the mITT popula-
tion are summarized in Table 1. All baseline characteristics
were comparable between groups. The patients enrolled showed
significant LV dysfunction and significantly reduced functional
capacity with a mean LVEF of 26+ 5%, and a mean peak VO2 of
12.2+ 1.8 mL/kg/min. Baseline concomitant HF medications are
summarized in Table 2.
For the patients undergoing the alginate-hydrogel procedure, the
mean procedure duration was 81+ 25 min, ranging from 50 to
160 min. The median ICU length of stay (LOS) was 2 days and
median hospital LOS was 15 days. The mean number of intra-
myocardial implants/injections for patients undergoing the alginate-
hydrogel procedure was 16+ 2, ranging from 11 to 19 (Table 3).
Cardiopulmonary exercise testing
Mean peak VO2 gradually increased over time in patients in the
alginate-hydrogel group while it remained unchanged in the Control
group (Figure 2A). Alginate-hydrogel treatment was associated with
improvement in peak VO2 compared with Control treatment; the
mean treatment effect was an increase of 1.24 mL/kg/min (95% con-
fidence interval, CI 0.26–2.23, P ¼ 0.014).
The improvement in peak VO2 was accompanied by a 1.0 min (P ¼
0.001) improvement in total treadmill exercise time (Figure 2B) and a
10 W improvement in maximum workload (P, 0.001). The peak ex-
ercise RER remained unchanged over time from baseline (1.02+
0.09) to 3 months (1.03+0.12) and 6 months (1.02+0.11).
In subgroup analyses, neither aetiology of HF (ischaemic vs. non-
ischaemic; P-value for interaction 0.066) nor baseline peak VO2
(greater than or ≤12.5 mL/kg/min; P-value for interaction 0.23) had
a significant interaction for treatment effect. Also for 15 pre-specified
subgroups analysed, there were no significant treatment-by-subgroup
interactions for the primary endpoint with the exception of the sub-
groups of patients split by median 6MWT distance at baseline (P-value
for interaction 0.014). Regional analysis did not find a significant inter-
action for treatment effect; results were the same for patients from
Romania (n ¼ 45) compared with patients from all other countries
(n ¼ 28).
Six-minute walk test distance
Mean 6MWT distance increased over time in patients in the
alginate-hydrogel group while mean 6MWT distance remained
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline demographics
Alginate-hydrogel
(n 5 35)a
Control
(n5 38)
Age (years) 63.1+10.1 62.1+9.2
Male 27 (77%) 34 (90%)
Ethnicity (white) 35 (100%) 38 (100%)
Ischaemic HF 20 (57%) 22 (58%)
Non-ischaemic HF 15 (42.9%) 16 (42.1%)
NYHA functional class (mean) 2.9+0.4 2.8+0.5
Class II/III/IV 5/28/2 9/26/3
LVEF (%) 25.4+5.3 25.6+5.0
Peak VO2 (mL/kg/min) 12.1+1.8 12.2+1.8
6MWT distance (m) 275+86 310+80
Mitral regurgitation ≥3+ 15 (43%) 22 (58%)
Hypertension 20 (57%) 23 (61%)
Diabetes 12 (34%) 17 (45%)
Atrial fibrillation 16 (40.0%) 37 (47.4%)
Stroke (CVA) 4 (11%) 5 (13%)
Prior myocardial infarction 22 (55.0%) 39 (50.0%)
Previous PCI or CABG 9 (26%) 11 (29%)
CRT 5 (14%) 5 (13%)
ICD 10 (29%) 9 (24%)
Control, standard medical therapy alone; n, number of patients; 6MWT, 6-min walk
test; HF, heart failure; CVA, cardio vascular accident; PCI, percutaneous coronary
intervention; CABG, coronary artery bypass grafting.
aModified intention-to-treat population; data are mean+ SD or patients (%).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Concomitant heart failure and cardiac
medications at baseline
Alginate-hydrogel
(n5 35)
Control
(n 5 38)
Diuretics 34 (97%) 38 (100%)
b-Blockers 33 (94%) 37 (97%)
ARB/ACEi 30 (86%) 35 (92%)
Mineralocorticoid receptor
antagonists
26 (74%) 25 (66%)
Anti-thrombotics or
anti-platelet agentsa
34 (97%) 38 (100%)
Anti-platelet aggregation agentsa 27 (77%) 21 (55%)
Anti-coagulanta 17 (49%) 24 (63%)
Lipid lowering 25 (71%) 27 (71%)
Data are number of patients.
Control, standard medical therapy alone; n, number of patients.
aNot mutually exclusive.
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unchanged or declined for patients in the Control group (P, 0.001,
change in median 6MWT distance +141 m, Figure 3).
New York Heart Association assessment
The NYHA functional class at 6 months was improved in the Algisyl
group, with 84% having an NYHA functional class I or II, when com-
pared with 26% in the Control group (odds ratio for improvement
by one class: 30.2; 95% CI 5.7–160.5, P, 0.001, Figure 4).
Quality of life
There were no statistically significant differences between groups
for any of the 10 KCCQ domain scores (Table 4). The self-reported
PGA at 6 months was improved in the Algisyl group with .55% of
patients reporting that they were much or moderately improved,
when compared with 28% of patients in the placebo group (odds ra-
tio for being in a better rank, 3.2; 95% CI 1.2–8.6, P ¼ 0.019).
Echocardiographic findings
Echocardiograms were performed at baseline and again at 3 and 6
months. While a majority of patients had an interpretable pre-
and post-study, there was a significant amount of missing data due
to various technical limitations for many studies. There were no
statistically significant differences between treatment groups for
any of the echocardiographic measures (Table 5).
Safety profile
In total, three deaths occurred during the 30-day period after the
surgical procedure to implant the alginate-hydrogel device. The
30-day absolute mortality rate was 8.57% (95% CI: 1.80–23.06%).
The 30-day absolute mortality rate in the Control group (no sur-
gery) was 0%. The major surgical complication rate for the alginate-
hydrogel device procedure was 25% (safety population).
The overall incidence of serious adverse events (SAEs) through
6 months of follow-up was not significantly different between the
alginate-hydrogel and Control group (Table 6). There were also
no statistically significant differences between treatment and control
for any of the categories of SAEs by body system or preferred term.
The incidence of SAEs of Cardiac Disorders was generally reported
to be more common among patients in the Control group com-
pared with patients in the alginate-hydrogel group.
Overall, MACE, excluding the index hospitalization, were lower
for patients receiving alginate-hydrogel and appears to be due to
substantially lower rates of worsening HF and sustained ventricular
arrhythmias in patients receiving the alginate-hydrogel device. The
incidence of CEC adjudicated secondary safety endpoints and
MACE are summarized in Tables 7 and 8. The study was not
powered to detect differences in either overall MACE or specific
categories of events. The listing of causes for non-heart failure hos-
pitalizations is provided in Table 10.
Analysis of 24-h-Holter monitors demonstrated no statistically
significant differences between groups for measures of supraventri-
cular or ventricular ectopy. There was no increase in ventricular
arrhythmias observed for patients receiving alginate-hydrogel.
Discussion
A large number of patients have symptomatic HF, despite the use of
all available guideline recommended treatments.11 The therapeutic
options for patients with advanced HF who have become refractory
to the currently available medical therapies (pharmacologic and
device) are limited;12 there is an unmet need for new therapeutic
options for this growing patient population.13
The AUGMENT-HF trial provides the first evidence that surgical
treatment with alginate-hydrogel in addition to standard medical
therapy was more effective than standard medical therapy alone
for improving exercise capacity and symptoms in patients with ad-
vanced HF. The results of AUGMENT-HF provide proof of concept
that intracardiac injection of alginate-hydrogel leads to beneficial ef-
fects in patients with advanced chronic HF and hence warrant further
studies to validate the observed effects and to extend them in greater
and possibly broader study populations with longer follow-up.
The baseline demographics for the study population represent a
group of patients with advanced chronic HF that is very well treated.
It is rare in clinical trials of ambulatory HF patients, that the patients
studied show a mean peak VO2 at baseline that is as low as 12.2 mL/
kg/min, with all patients having values of 14.5 mL/kg/min or less.
These results are based on the average of two qualifying maximum
exercise tests, and hence are not the result of a possible under-
performance during the learning curve experience of patients.
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Table 3 Summary details of operative procedure and
index hospitalization
Alginate-hydrogel
(n5 35)a
Procedure duration (min)
Mean (SD) 80.5 (24.9)
Median (min–max) 78 (50–160)
Anesthesia duration (min)
Mean (SD) 190 (29)
Median (min–max) 184 (120–240)
Total number of alginate-hydrogel implants (injections)
Mean (SD) 15.5 (2.0)
Median (min–max) 15 (11–19)
Total volume administered (mL)
Mean (SD) 4.6 (0.6)
Median (min–max) 4.5 (3.3–5.7)
ICU length of stay (days)
Mean (SD) 4.3 (7.3)
Median (min–max) 2 (1–43)
Hospital length of stay (days)
Mean (SD) 18.4 (13.0)
Median (min–max) 15 (7–65)
Control, standard medical therapy alone; n, number of patients; SD, standard
deviation; min, minimum; max, maximum; perc, percentile; ICU, intensive care unit;
Index surgical procedure, procedure to implant the alginate-hydrogel device.
aModified intention-to-treat population.
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We consider the treatment effect of 1.24 mL/kg/min for changes
in peak VO2 over 6 months as an important observation for this pa-
tient population. It represents a 10.2% improvement over baseline.
Sarullo et al. reported that clinically stable HF patients with a peak
VO2,12.2 mL/kg/min had a 1-year cardiovascular mortality of 66%
and a 1-year cardiovascular hospitalization rate of 63%, while pa-
tients with a peak VO2 .12.2 mL/kg/min had rates of only 34 and
37%, respectively.14 Swank et al. reported that for every 6% increase
in peak VO2 there was an 8% reduction in cardiovascular mortality
or HF hospitalization and a 7% reduction in all-cause mortality.15 In
this context, it is interesting that a secondary per-protocol analysis
found that alginate-hydrogel provided an improvement in peak VO2
compared with patients in the Control group with a mean treatment
effect of 1.59 mL/kg/min (P ¼ 0.002).
It is an interesting observation that the mean 6MWT distance in
the alginate-hydrogel group at baseline was substantially below the
300 m threshold and was observed to increase above the 300 m
threshold at the 3- and 6-month follow-up visits. Several studies
have demonstrated that a 6MWT distance of ,300 m is strongly
prognostic of subsequent mortality and hospital admission in stable
chronic HF16,17 and in patients with advanced HF.18 Many consider
that an improvement of .50 m in 6MWT distance is clinically very
meaningful,19,20 and changes between 30 and 50 m for 6MWT dis-
tance are also often considered clinically relevant.21 The improve-
ment of 6MWT distance for alginate-hydrogel-treated patients in
AUGMENT-HF was .100 m, and hence was an interesting finding.
Still, this finding needs to be validated.
Figure 2 (A) Peak VO2 at 6 months: mean change (from baseline). (B) Peak watts at 6 months: mean change (from baseline). (C) Maximum
exercise time at 6 months: mean change (from baseline). Control, standard medical therapy; SE, standard error; P-value, (adjusted) mean product
effect.
Figure 3 Six-minute walk test distance at 6 months. Control,
standard medical therapy; 6MWT, 6-min walk test.
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The improvements in peak VO2, 6MWT, and NYHA class in
AUGMENT-HF provide a demonstration of a possible clinical bene-
fit for the alginate-hydrogel device treatment. The results provide
proof of concept for this new treatment approach. The results re-
quire validation and extension in larger patient cohorts that are fol-
lowed for longer periods of times. A pivotal trial to this end is in the
planning phase.
The alginate-hydrogel implant acts as a permanent prosthetic
scaffold that aims to reduce wall stress, and prevent further LV en-
largement based on the physical principles described in Laplace law.
Previously, surgical ventricular restoration (SVR) and devices em-
ploying LV reshaping strategies were evaluated in clinical studies
such as the STICH trial25 the ACORN trial9 of the CorCap device
(Acorn) and the PEERLESS-HF trial22 of the HeartNet device (Para-
cor Medical Inc.). The goals of SVR were to reduce the increased ra-
dius of curvature present in a dilated heart, and both the CorCap
and HeartNet devices aimed to restrict and reverse LV dilatation;
however, neither of these devices were approved for clinical use
and the large multi-centre STICH trial failed to demonstrate a clin-
ical benefit of SVR combined with CABG compared with CABG
alone. More recently, other LV reshaping approaches include the
Parachute device (Cardikinetix)23 to reduce the size of the LV cavity
with an insert and the Revivent device (Bioventrix)24 to isolate big
dysfunctional regions of the LV. Results from controlled randomized
intervention trials are not yet available for these.
The procedural success of the alginate-hydrogel injection
approach was 100% in this trial. The mean operative procedure
time of 80.5 min demonstrated that in most patients the alginate-
hydrogel device is implanted with relative ease in the context of
a limited surgical procedure. These procedure metrics compare
favourably with many current commonly performed ‘non-surgical’
procedures performed in patients with advanced structural heart
disease. This is an important consideration, since both prolonged
operative time and anaesthesia time are associated with increased
rates of complications. The overall hospital LOS was longer than
expected with a median of 15 days. However, there was no
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Table 4 Mean (Kansas City Cardiomyopathy Questionnaire) scores and changes from screening values
KCCQ domain Visit Alginate-hydrogel Control P-value
between
groupsn Mean+ SD n Mean+ SD
Overall summary Baseline 35 47+21 37 49+22
6-month 29 65+25 34 60+23 0.12
Clinical summary Baseline 35 52+21 37 55+22
6-month 29 69+26 34 64+21 0.14
Quality of life Baseline 35 39+27 37 42+26
6-month 29 63+27 34 54+26 0.066
Total symptom Baseline 35 58+22 37 61+25
6-month 29 74+26 34 68+22 0.11
Social limitation Baseline 35 45+27 36 45+28
6-month 28 60+32 33 58+28 0.46
Self-efficacy Baseline 35 71+25 37 78+18
6-month 28 80+21 34 79+18 0.16
Symptom burden Baseline 35 60+23 37 61+25
6-month 29 74+26 34 68+22 0.22
Symptom frequency Baseline 35 55+24 37 62+25
6-month 29 74+28 34 67+24 0.079
Symptom stability Baseline 34 52+21 37 52+27
6-month 29 61+22 34 48+25 0.072
Physical limitation Baseline 35 47+21 37 48+25
6-month 29 64+27 34 61+24 0.31
Control, standard medical therapy alone; n, number of available values; SD, standard deviation.
Figure 4 New York Heart Association functional class at
6 months. Control, standard medical therapy; n, number of avail-
able values.
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suggestion that this was a result of complications or a complica-
ted post-operative course in general. Excluding all 22 patients
who experienced an adverse event during the index hospitaliza-
tion (within 30 days after surgery) results in a median LOS of
12.5 days, i.e. it did not significantly change overall hospital LOS.
Hence, the longer than expected LOS appears to be a reflection
of a cautious approach by investigators to discharge patients
home following this initial experience with a novel device and
procedure.
The 30-day all-cause mortality associated with the implantation of
the alginate-hydrogel device was the primary safety endpoint for this
study. In total, three deaths occurred during the 30-day period after
the surgical procedure to implant the alginate-hydrogel device
(8.57% in the mITT population, 95% CI 1.80–23.06%) (Table 9).
This met the primary safety endpoint for the study, and it is compar-
able with mortality rates observed in prior reports of surgical
device-based therapies for HF. For example, Mann et al.9 reported
a 30-day mortality of 7.8% for advanced HF patients receiving
the Acorn CorCap device, and Grossi et al.10 reported a 30-day
mortality of 8.1% for advanced HF patients receiving the Myocor
Coapsys device.
The major surgical complication rate for the alginate-hydrogel de-
vice procedure was 25%. Overall, 6-month mortality was higher for
patients receiving the alginate-hydrogel device with six deaths com-
pared with three in the Control group. The 30-day MACE rate
during the index hospitalization was 15%. The 6-month MACE
rate excluding the index hospitalization was lower for patients re-
ceiving alginate-hydrogel and mostly appears to have been attribu-
ted to lower rates of hospitalizations due to worsening HF.
Conclusions from this information are not possible, as power is lim-
ited and none of the differences were significant.
An important consideration for assessing the risks of the
alginate-hydrogel therapy will be observations of long-term mor-
tality and longer term clinical benefits from longer follow-up and
future studies. These data will provide important context on
whether the early risks associated with surgery can be offset by
later benefits.
A theoretical concern of intra-myocardial injections/implants is
that they could be a basis for sustained ventricular arrhythmias as
seen with the prior experience of myoblast therapy. Therefore,
the absence of any increase in ventricular arrhythmia or ventricular
ectopy in alginate-hydrogel patients is reassuring.
Thus the results of the AUGMENT-HF trial suggest that
alginate-hydrogel can be administered safely in patients with
advanced HF.
Limitations
A primary limitation of this current study is the lack of blinding for
the assignment of patients to surgical device therapy. Endpoints such
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Table 6 Summary of adverse events
Alginate-hydrogel (n 5 35) Control (n5 38) HR (95% CI) P
Total no.
of events
No. of patients with
events (incidence per
100 patient-years at risk)
Total no.
of events
No. of patients with
events (incidence per
100 patient-years at risk)
All adverse events 115 31 (489.1) 63 17 (119.1) 3.41 (1.87–6.22) ,0.001
Serious adverse events 33 16 (135.4) 26 10 (63.0) 2.08 (0.94–4.60) 0.063
Control, standard medical therapy alone; n, number of patients; HR, hazard ratio; CI, confidence interval. P, log-rank P-value.
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Table 5 Transthoracic echocardiogram mean (standard deviation) values and changes from screening values for
selected parameters
Visit Alginate-hydrogel Control P-value
between
groupsn Mean+ SD n Mean+ SD
LVEDD (cm) Baseline 33 6.3+0.40 34 6.4+0.50
6-month 26 6.0+0.42 33 6.2+0.47 0.17
LVESD (cm) Baseline 33 5.5+0.52 34 5.7+0.56
6-month 26 5.2+0.65 34 5.4+0.59 0.091
LVEF (%) Baseline 34 25+5 36 26+5
6-month 28 28+5 34 28+6 0.61
LV mass (g) Baseline 33 296+59 34 317+59
6-month 25 275+63 33 300+56 0.44
Control, standard medical therapy alone; n, number of available values; SD, standard deviation.
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Table 7 Major adverse cardiac events excluding index hospitalization
Event Modified ITT HR (95% CI) P-value ITT HR (95% CI) P-value
Alginate-hydrogel
(n 5 35)
Control (n5 38) Alginate-hydrogel
(n 5 40)
Control (n5 38)
Total
no. of
events
No. of patients
with events
(incidence per
100 patient-years
at risk)
Total
no. of
events
No. of patients
with events
(incidence per
100 patient-years
at risk)
Total
no. of
events
No. of patients
with events
(incidence per
100 patient-years
at risk)
Total
no. of
events
No. of patients
with events
(incidence per
100 patient-years
at risk)
All-cause death 6 6 (38.4) 3 3 (16.6) 2.32 (0.58–9.26) 0.22 6 6 (37.3) 3 3 (16.6) 2.26 (0.57–9.05) 0.24
Cardiovascular death 5 5 (32.0) 3 3 (16.6) 1.94 (0.46–8.11) 0.36 5 5 (31.1) 3 3 (16.6) 1.89 (0.45–7.93) 0.37
MACE events (excluding
index hospitalization)
9 7 (47.2) 22 10 (61.3) 0.78 (0.30–2.04) 0.61 9 7 (45.8) 22 10 (61.3) 0.76 (0.29–2.00) 0.58
All-cause
hospitalization
18 10 (76.4) 27 12 (75.9) 1.01 (0.44–2.34) 0.98 18 10 (73.9) 27 12 (75.9) 0.98 (0.42–2.27) 0.96
Heart failure
hospitalization
5 4 (26.8) 14 8 (48.4) 0.56 (0.17–1.85) 0.33 5 4 (26.0) 14 8 (48.4) 0.54 (0.16–1.80) 0.31
All-cause
hospitalization or
CV death
23 13 (99.6) 30 12 (75.9) 1.30 (0.59–2.85) 0.51 23 13 (96.2) 30 12 (75.9) 1.26 (0.57–2.76) 0.56
HF hospitalization or
CV death
10 9 (60.7) 17 8 (48.4) 1.25 (0.48–3.25) 0.64 10 9 (58.9) 17 8 (48.4) 1.22 (0.47–3.17) 0.68
Major adverse cardiac event are defined as cardiac death, cardiac arrest, myocardial infarction, sustained ventricular arrhythmias, pulmonary oedema, acute HF, unstable angina, and major bleeding.
P-value, log-rank P-value; MACE, major adverse cardiac events; HF, heart failure; CV, cardiovascular; N, number of patients; HR, hazard ratio; CI, confidence interval.
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as exercise testing (which depend on patient effort) and subjective
endpoints such as NYHA functional class can be subject to bias in a
non-blinded trial. We used blinded core laboratory assessments
wherever possible to generate valid data as much as possible. Add-
itionally, the limited sample size (35 patients undergoing the surgical
device procedure) requires some caution when drawing conclu-
sions and a larger trial experience will be needed to validate the
findings.
The mean RERs for the study cohort were ,1.05 at all-time
points and in both treatment groups. However, the 25th to
75th percentile of RER was 0.95–1.08 and the 25th to 75th per-
centile were also essentially unchanged across the visits. While an
RER .1.05 or 1.10 is often used as a criterion to judge presence
of a maximum effort during CPX, prior reports have observed
that a very large percentage of chronic HF patients are unable
to achieve an RER of .1.00 when performing the CPX test.28
The consistency of the RER over the course of the study and
the duplication of exercise tests at important time points suggest
that the changes in peak VO2 over time were not a result of
changes in effort and support the consistency and reproducibility
of the test results.
None of the echocardiographic measures in this study reached
statistical significance for the group comparisons. This is not surpris-
ing given the small size with respect to measures of echocardiog-
raphy. Additionally, many HF therapies require relatively long
time periods to reach a maximal effect or demonstrate reverse re-
modelling. It is possible that a longer observation period is needed
to realize the full impact of alginate-hydrogel treatment on measures
LV remodelling. Future studies need to study cardiac function in
more detail.
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Table 8 Overall major adverse cardiac events
Event Modified ITT ITT
Alginate-hydrogel
(n5 35)
Control (n 5 38) Alginate-hydrogel
(n5 40)
Control (n5 38)
Total no.
of events
No. of
patients (%)
Total no.
of events
No. of
patients (%)
Total no.
of events
No. of
patients (%)
Total no.
of events
No. of
patients (%)
Overall MACE 18 11 (31.4%) 22 10 (26.3%) 18 11 (27.5%) 22 10 (26.3%)
MACE during index
hospitalization
9 6 (17.0%) NA 9 6 (15.0%) NA
Cardiovascular death 2 2 (5.7%) NA 2 2 (5.0%) NA
Cardiac arrest 2 2 (5.7%) NA 2 2 (5.0%) NA
Worsening HF 1 1 (2.9%) NA 1 1 (2.5%) NA
Major bleeding 3 3 (8.6%) NA 3 3 (7.5%) NA
Sustained ventricular
arrhythmias
1 1 (2.9%) NA 1 1 (2.5%) NA
Major adverse cardiac events are defined as cardiac death, cardiac arrest, myocardial infarction, sustained ventricular arrhythmias, pulmonary oedema, acute HF, unstable angina,
and major bleeding.
Overall, MACE include all MACE from baseline to 6 months (including index hospitalization).
MACE, major adverse cardiac events; N, number of patients.
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Table 9 Listing of cause of death
Patient ID Study group CEC adjudication Days post-randomization
RO-48-0063 Alginate-hydrogel Cardiovascular Intra-cranial haemorrhage 28
RO-44-0095 Alginate-hydrogel Cardiovascular Sudden death witnessed 32
RO-47-0083 Alginate-hydrogel Cardiovascular Non-haemorrhagic stroke 33
RO-44-0071 Control Cardiovascular Cardiac arrest 38
RO-44-0017 Control Cardiovascular Congestive HF/cardiogenic shock 39
RO-44-0019 Alginate-hydrogel Non-cardiovascular Infection (including sepsis) 69
NL-32-0026 Alginate-hydrogel Cardiovascular Congestive HF/cardiogenic shock 85
RO-44-0069 Alginate-hydrogel Cardiovascular Other vascular: 10 days following cardiac transplant 165
IT-21-0035 Control Cardiovascular Congestive HF/cardiogenic shock 165
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Conclusion
The AUGMENT-HF trial documents that surgical treatment with
alginate-hydrogel was effective in improving exercise capacity and
symptoms in patients with advanced chronic HF. The safety profile
of this device treatment is acceptable. Further clinical trial experi-
ence is needed to validate these promising results.
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Table 10 Listing of causes for non-heart failure hospitalizations
Patient ID Study group Hospitalization Investigator event term Fatal
outcome
CEC
adjudicated
AU-38-0010 Alginate-hydrogel 1 Central chest pain No NA
2 Continuation of atypical centralized chest pain
AU-38-0070 Alginate-hydrogel 3 Acute injury of chronic renal failure No NA
Worsening bilateral peripheral oedema
IT-20-0016 Alginate-hydrogel 4 Lobar right pneumonia No NA
IT-20-0094 Alginate-hydrogel 5 Erysipelas bilateral lower limbs No NA
6 Worsening HF
Septic shock due to legionella pneumonia
Acute cholangitis
IT-20-0109 Alginate-hydrogel 7 Hemisyndrome facio-brachio-crural right No NA
8 Hypertensive crisis associated with pulmonary oedema
9 Respiratory infection
10 Syndrome of Dressler
NL-32-0026 Alginate-hydrogel 11 Sepsis Yes CV
Haematoma at location of surgery wound
Critical illness polyneuropathy syndrome secondary to sepsis
RO-44-0019 Alginate-hydrogel 12 Right-sided pneumonia with poliresistant Klebsiella Yes Non-CV
RO-44-0069 Alginate-hydrogel 13 Cardiac transplant Yes CV
DE-16-0096 Control 14 Worsening of mitral function No NA
15 Symptomatic persistent atrial fibrillation
IT-18-0057 Control 16 Symptomatic tachycardia No NA
IT-49-0048 Control 17 Supraventricular tachycardia provoking two ICD shocks No NA
RO-44-0055 Control 18 Syncope No NA
RO-44-0071* Control 19 Worsening of HF No NA
RO-47-0054 Control 20 Sustained ventricular tachycardia No NA
RO-48-0046 Control 21 Interstitial pneumonia No NA
Planned hospitalization for assessment for cardiac transplantation
22 Worsening of HF
23 Planned hospitalization for cardiac catheterism
24 Junctional rhythm
25 Planned hospitalization for investigation for cardiac transplantation
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Table 11 Assignment of patients by country
Informed
consent
Screening
failure
Randomized (% of randomized) Surgery (% of randomized to
Algisyl-LVR)
Control Alginate-hydrogel Did not perform
surgery
Alginate-hydrogel
implanted
All patients 113 35 (31.0%) 38 (48.7%) 40 (51.3%) 5 (12.5%) 35 (87.5%)
Australia 3 1 (33.3%) 0 (0.0%) 2 (100.0%) 0 (0.0%) 2 (100.0%)
Germany 7 4 (57.1%) 2 (66.7%) 1 (33.3%) 1 (100.0%) 0 (0.0%)
Italy 45 21 (46.7%) 10 (41.7%) 14 (58.3%) 2 (14.3%) 12 (85.7%)
The Netherlands 5 3 (60.0%) 1 (50.0%) 1 (50.0%) 0 (0.0%) 1 (100.0%)
Romania 52 5 (9.6%) 25 (53.2%) 22 (46.8%) 2 (9.1%) 20 (90.9%)
Data are number of patients (%).
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